
The FDA approved adrabetadex for infantile-onset NPC based on a 55% lower risk of death vs external controls, with a boxed warning for hearing loss.
We know that there is so much for you to read and only so much time. To help you get through that stack of reading, we've picked 5 studies to highlight.






